Raloxifene-associated hepatitis

Raloxifene-associated hepatitis

Vilches et al examine the case of a postmenopausal woman who was started on raloxifene and calcium carbonate as therapy for bone loss. The patient developed hepatitis of the liver as a result of the therapy.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 352; no. 9139; pp. 1524 - 1525
Main Authors: Vilches, Antonio R, Pérez, Victor, Suchecki, Dora Eva
Format: Journal Article
Language:English
Published: London Elsevier Ltd 07-11-1998
Lancet
Elsevier Limited
Subjects:
Biological and medical sciences
Bone Density
Calcium carbonate
Chemical and Drug Induced Liver Injury - etiology
Drug therapy
Drug toxicity and drugs side effects treatment
Estrogen Antagonists - adverse effects
Estrogen Antagonists - therapeutic use
Estrogens - agonists
Female
Hepatitis
Humans
Liver
Medical sciences
Middle Aged
Osteoporosis
Pharmacology. Drug treatments
Piperidines - adverse effects
Piperidines - therapeutic use
Postmenopause
Raloxifene Hydrochloride
Toxicity: digestive system
Women
Human
Toxicity
Liver
Diseases of the osteoarticular system
Hepatic disease
Bone disease
Case study
Hepatitis
Osteoporosis
Chemotherapy
Treatment
Digestive diseases
Female
Raloxifene
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vilches et al examine the case of a postmenopausal woman who was started on raloxifene and calcium carbonate as therapy for bone loss. The patient developed hepatitis of the liver as a result of the therapy.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(05)60331-5